Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 30;62(2):154-164.
doi: 10.3325/cmj.2021.62.154.

B regulatory cells and monocyte subpopulations in patients with chronic graft-vs-host disease

Affiliations

B regulatory cells and monocyte subpopulations in patients with chronic graft-vs-host disease

Antonija Babić et al. Croat Med J. .

Abstract

Aim: To assess the correlations of B regulatory cells (Bregs) and monocyte subsets in peripheral blood with the National Institutes of Health (NIH)-consensus-defined clinical manifestations of chronic graft-vs-host disease (cGvHD), in an attempt to establish their role as cellular biomarkers.

Methods: This multidisciplinary prospective study enrolled adult cGVHD patients treated in the University Hospital Center Zagreb and University of Zagreb School of Medicine. Immunophenotypic subpopulations of CD24highCD38high Bregs (CD27-, CD27+, and total) and monocyte (classical, intermediate, and non-classical) counts were correlated with demographic, transplant, and cGVHD-related data. Bivariate correlation analysis was performed to evaluate the correlations between Bregs and monocytes subsets and cGVHD organ involvement, as well as cGVHD severity and immunosuppression intensity.

Results: Twenty-two adult patients (54.5% female) with cGVHD were enrolled. The median (range) age was 44.5 years (24-65). All patients were transplanted for hematologic malignancies and 40.9% had severe NIH cGVHD global score. The median time from cGVHD diagnosis to the analysis was 16.6 months (0-176). The organ most frequently affected with cGVHD were the eyes (68.2%), skin (45.5%), lungs (45.5%), and liver (40.9%). Lower total and CD27-Bregs counts were correlated with worse cGVHD severity, higher immunosuppression intensity, and lung cGVHD, in terms of cell count, but also with skin cGVHD, in terms of percentages. Patients with liver and joint/fascia cGVHD had a lower percentage of non-classical monocytes and patients with more severe global NIH score had a higher classical monocytes count.

Conclusion: Different organs affected by cGVHD are differently associated with different subpopulations of Bregs and monocytes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Regulatory B cells were gated from CD19 positive cells as CD24++CD38++ cells. (B) Monocyte subpopulations were gated from HLA-DR positive cells according to CD14 and CD16 expression as non-classical (CD14+CD16++), intermediate (CD14++CD16+), and classical monocytes (CD14++CD16-). Abbreviations: HLA-DR– human leukocyte antigen-DR; FITC-A – fluorescein isothiocyanate; SSC-A – side scatter; APC-A –allophycocyanin.
Figure 2
Figure 2
(A) Total regulatory B cell count in patients according to their chronic graft vs host disease lung involvement. (B) Total classical monocytes count in patients according to their global National Institutes of Health score.

References

    1. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33. doi: 10.1053/bbmt.2003.50026. - DOI - PubMed
    1. Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–15. doi: 10.1182/blood-2014-08-551994. - DOI - PMC - PubMed
    1. Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377:2565–79. doi: 10.1056/NEJMra1703472. - DOI - PubMed
    1. Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017;23:211–34. doi: 10.1016/j.bbmt.2016.09.023. - DOI - PMC - PubMed
    1. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21:389–401.e1. doi: 10.1016/j.bbmt.2014.12.001. - DOI - PMC - PubMed